Display options
Share it on

Am J Cancer Res. 2021 Jun 15;11(6):3227-3239. eCollection 2021.

[No title available]

American journal of cancer research

Michelle D Williams, Junsheng Ma, Elizabeth G Grubbs, Robert F Gagel, Rozita Bagheri-Yarmand

Affiliations

  1. Department of Pathology, The University of Texas MD Anderson Cancer Center Houston, Texas, USA.
  2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, Texas, USA.
  3. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center Houston, Texas, USA.
  4. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center Houston, Texas, USA.

PMID: 34249457 PMCID: PMC8263636

Abstract

Activating transcription factor 4 (ATF4) is a crucial mediator of the integrated stress response and a negative regulator of RET tyrosine kinase receptor in medullary thyroid carcinoma (MTC). However, the impact of genomic abnormalities in the

AJCR Copyright © 2021.

Keywords: ATF4; RET; loss of heterozygosity; medullary thyroid carcinoma; tyrosine kinase inhibitors

Conflict of interest statement

None.

References

  1. Mol Cancer Ther. 2021 Apr;20(4):665-675 - PubMed
  2. Nat Cell Biol. 2013 May;15(5):481-90 - PubMed
  3. Int J Oncol. 1998 Oct;13(4):705-9 - PubMed
  4. J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877 - PubMed
  5. World J Gastroenterol. 2002 Aug;8(4):668-73 - PubMed
  6. Br J Pharmacol. 2018 Sep;175(17):3504-3515 - PubMed
  7. Ann Surg Oncol. 2010 Jun;17(6):1471-4 - PubMed
  8. Am J Pathol. 1999 May;154(5):1539-47 - PubMed
  9. Int J Oncol. 2001 Jun;18(6):1219-25 - PubMed
  10. Genes Chromosomes Cancer. 1993 Mar;6(3):166-77 - PubMed
  11. J Natl Compr Canc Netw. 2010 May;8(5):549-56 - PubMed
  12. Ann Oncol. 2018 Aug 1;29(8):1869-1876 - PubMed
  13. Trends Endocrinol Metab. 2017 Nov;28(11):794-806 - PubMed
  14. Oncogene. 2001 Nov 22;20(53):7809-11 - PubMed
  15. Jpn J Cancer Res. 1987 Sep;78(9):894-8 - PubMed
  16. Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73 - PubMed
  17. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12269-74 - PubMed
  18. J Biol Chem. 2015 May 1;290(18):11749-61 - PubMed
  19. J Clin Endocrinol Metab. 2017 Mar 1;102(3):933-941 - PubMed
  20. Mol Cell. 2014 Mar 6;53(5):738-51 - PubMed
  21. Genes Chromosomes Cancer. 1992 Nov;5(4):399-403 - PubMed
  22. Am J Surg Pathol. 2004 Jan;28(1):101-6 - PubMed
  23. Int J Cancer. 2012 Jul 15;131(2):E66-73 - PubMed
  24. Hepatology. 1993 May;17(5):794-9 - PubMed
  25. Theranostics. 2019 Aug 14;9(21):6334-6353 - PubMed
  26. Recent Results Cancer Res. 2015;204:227-49 - PubMed
  27. Oncogene. 2016 Feb 4;35(5):537-48 - PubMed
  28. J Clin Oncol. 2012 Jan 10;30(2):134-41 - PubMed
  29. J Clin Endocrinol Metab. 2008 Nov;93(11):4367-72 - PubMed
  30. J Clin Invest. 1991 May;87(5):1691-9 - PubMed
  31. EMBO Rep. 2016 Oct;17(10):1374-1395 - PubMed
  32. J Clin Endocrinol Metab. 2003 Apr;88(4):1866-72 - PubMed
  33. Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73 - PubMed
  34. BMC Cancer. 2006 May 17;6:131 - PubMed
  35. Cancer Res. 2000 Jun 1;60(11):2836-9 - PubMed
  36. Cancer Discov. 2018 Jul;8(7):836-849 - PubMed
  37. Recent Results Cancer Res. 1998;154:271-81 - PubMed
  38. Cancer Res. 2000 Nov 15;60(22):6223-6 - PubMed
  39. Recent Results Cancer Res. 2015;204:1-39 - PubMed
  40. Head Neck. 2000 Sep;22(6):585-90 - PubMed
  41. Mol Cancer Res. 2019 Mar;17(3):751-760 - PubMed
  42. Cell Death Differ. 2006 Apr;13(4):619-27 - PubMed
  43. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591-3599 - PubMed
  44. Genomics. 2000 Nov 1;69(3):391-4 - PubMed
  45. Endocr Relat Cancer. 2020 Aug;27(8):T27-T39 - PubMed
  46. J Cell Biol. 2017 Jul 3;216(7):2027-2045 - PubMed

Publication Types